Last reviewed · How we verify

Asahi Kasei Pharma Corporation — Portfolio Competitive Intelligence Brief

Asahi Kasei Pharma Corporation pipeline: 0 marketed, 0 filed, 4 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 4 Phase 3 2 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
AK1820 AK1820 phase 3
Mizoribine (MZR) Mizoribine (MZR) phase 3 IMPDH inhibitor; immunosuppressant IMPDH (inosine monophosphate dehydrogenase) Immunology; Transplantation
Cyclophosphamide (CTX) Cyclophosphamide (CTX) phase 3 Alkylating agent DNA (non-specific alkylation) Oncology, Immunology
AK156 AK156 phase 3 PD-1 inhibitor PD-1 Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Memorial Sloan Kettering Cancer Center · 2 shared drug classes
  2. The Netherlands Cancer Institute · 2 shared drug classes
  3. H. Lee Moffitt Cancer Center and Research Institute · 2 shared drug classes
  4. Hospices Civils de Lyon · 2 shared drug classes
  5. Peking University People's Hospital · 2 shared drug classes
  6. Sun Yat-sen University · 2 shared drug classes
  7. Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
  8. Al-Azhar University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Asahi Kasei Pharma Corporation:

Cite this brief

Drug Landscape (2026). Asahi Kasei Pharma Corporation — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/asahi-kasei-pharma-corporation. Accessed 2026-05-16.

Related